Gansu Longshenrongfa Pharmaceutical IndustryLTD Valuation
Is 300534 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 300534 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 300534 für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 300534 für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300534?
Other financial metrics that can be useful for relative valuation.
| What is 300534's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥2.57b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.1x |
| Enterprise Value/EBITDA | 29.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 300534's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.2x | ||
688073 Bide Pharmatech | 28.9x | 48.6% | CN¥3.3b |
600774 Hanshang Group | 24.2x | n/a | CN¥2.2b |
605177 Zhejiang East Asia Pharmaceutical | 20x | n/a | CN¥2.6b |
600513 Jiangsu Lianhuan Pharmaceutical | 19.6x | n/a | CN¥2.6b |
300534 Gansu Longshenrongfa Pharmaceutical IndustryLTD | 45.4x | n/a | CN¥2.6b |
Price-To-Earnings gegen Gleichaltrige: 300534 ist auf der Grundlage des Price-To-Earnings Verhältnisses (55.8x) im Vergleich zum Durchschnitt der Vergleichsgruppe (25.9x) teuer.
Price to Earnings Ratio vs Industry
How does 300534's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 300534 ist teuer, wenn man sein Price-To-Earnings Verhältnis (42x) mit dem CN Pharmaceuticals Branchendurchschnitt (25.4x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is 300534's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 45.4x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von 300534 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.